Table 1.
Basic characteristic of the participants
| Variable | Value |
| Gender (F/M) | 3/7 |
| Age, years median (range) | 63 (44–75) |
| BMI (range) | 23.4 (19.6–26.0) |
| Concomitant disease | |
| Cardiovascular disease | 2 (20%) |
| Pulmonary disease | 1 (10%) |
| ASA score (1/2/3) | 7/2/1 |
| Neoadjuvant treatment | 10 (100%) |
| Cycles of chemotherapy (range) | 6 (5–6) |
| Interval between last chemotherapy and hepatectomy (weeks, range) | 4 (4–6) |
| Liver fibrosis stage a 0/1/2 | 3/5/2 |
| Liver fibrosis etiology: Chemotherapy | 10 (100%) |
| Signs of sinusoidal obstruction syndrome due to oxaliplatin chemotherapy (Yes/no) | 8/2 |
| Operation | |
| Right hemihepatectomy | 10 (100%) |
| Laparoscopic operation | 2 (20%) |
| Blood transfusion | 3 (30%) |
| Transfused Units (range) | 2 (1–4) |
| Radical resection (pR0/pR1) | 9/1 |
| Histology : CRLM | 10 (100%) |
ASA score, American Society of Anesthesiology score; BMI, body mass index; CRLM, colorectal liver metastasis.
pR0, > 1 mm from tumor to resection margin; pR1, < 1 mm from tumor to resection margin.
a
by the Batts-Ludwig scoring system, in which stage 0, 1 and 2 indicate no, mild and moderate fibrosis respectively (on a 5-graded scale);